Patent ID: 11883430
Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 13:
14. The method of claim 1, wherein the hybrid Th1/Th17 cells have reduced expression of CD38 as compared to Th1 or Th17 cells;
have at least two-fold higher Sirt1 activity as compared to Th17 cells;
co-express elevated levels of IFNγ and IL17;
express transcription factors T-bet, RORγ, and/or IRF-4;
express chemokine receptors CXCR3 and/or CCR6;
express effector genes GzmB, Tbx21, and/or GM-CSF;
express stemness genes IL22, IL23R, TCF7, BCL6, and/or β-catenin;
and/or exhibit increased anti-tumor activity as compared to Th1 or Th17 cells.